Atlas Trials

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

Clinical trial NCT02025712 · UNKNOWN

Trial details

NCT number
NCT02025712
Sponsor
Organisation for Oncology and Translational Research
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Hormone Receptor Positive Malignant Neoplasm of Breast
Primary completion
2016-08-01
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.